Great HVST(version) announcement re Satipharm to Australia. Note also that it says -
"For the Australian market, the capsules are currently available in a 10mg and a 50mg CBD presentation and contain no detectable levels of Tetrahydrocannabinol (THC). Other formulations that include THC are in development and will be introduced to the market in the near future."
In particular note how it refers to"Other formulations with THC and "near future" - so this is now getting closer - Yay!
It also implies that Satipharm would be distributing the new formulation.
Of course "the other formulations" have involved MMJ's Phytotech's ongoing research as previously advised.
I would expect that MMJ will be charging HVST's Satipharm for the rights to the new formulations either by contract licensing, but perhaps involve research fees, or royalties. This supposition relates to income for MMJ's Phytotech, (although nothing can be confirmed at this stage).
Phytotech also continues to work on the buccal patch development.
Some posters have been dismissing MMJ's operational income stream - please DYOR.
MMJ Price at posting:
38.0¢ Sentiment: Buy Disclosure: Held
